Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

FBIO

Fortress Biotech Inc

May 02 • 04:00PM ET

1.80

Dollar change +0.06
Percentage change 3.45	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF FESM

Index	-	P/E	-	EPS (ttm)	-21.66	Insider Own	28.32%	Shs Outstand	15.09M	Perf Week	4.65%
Market Cap	34.61M	Forward P/E	-	EPS next Y	-4.68	Insider Trans	47.93%	Shs Float	13.79M	Perf Month	-6.25%
Income	-66.66M	PEG	-	EPS next Q	-1.73	Inst Own	24.46%	Short Float	13.21%	Perf Quarter	-8.63%
Sales	84.51M	P/S	0.41	EPS this Y	29.40%	Inst Trans	-13.18%	Short Ratio	6.57	Perf Half Y	0.56%
Book/sh	1.49	P/B	1.21	EPS next Y	21.68%	ROA	-26.26%	Short Interest	1.82M	Perf Year	-84.28%
Cash/sh	4.21	P/C	0.43	EPS next 5Y	25.50%	ROE	-188.71%	52W Range	1.24 - 11.85	Perf YTD	-40.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	22.28%	ROI	-65.56%	52W High	-84.81%	Beta	1.65
Dividend TTM	-	Quick Ratio	1.26	Sales past 5Y	26.66%	Gross Margin	66.41%	52W Low	45.16%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	1.38	EPS Y/Y TTM	-57.11%	Oper. Margin	-164.76%	RSI (14)	48.70	Volatility	5.49% 6.69%
Employees	186	Debt/Eq	3.93	Sales Y/Y TTM	11.58%	Profit Margin	-78.88%	Recom	1.00	Target Price	13.00
Option/Short	Yes / Yes	LT Debt/Eq	3.51	EPS Q/Q	79.56%	Payout	-	Rel Volume	0.41	Prev Close	1.74
Sales Surprise	31.94%	EPS Surprise	52.58%	Sales Q/Q	21.59%	Earnings	Mar 28 AMC	Avg Volume	277.35K	Price	1.80
SMA20	0.31%	SMA50	-5.68%	SMA200	-47.04%	Trades		Volume	116,076	Change	3.45%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-15-24	Resumed	ROTH MKM	Buy	$10
Aug-04-22	Initiated	Ladenburg Thalmann	Buy	$6
Oct-02-20	Initiated	The Benchmark Company	Buy	$9
Dec-18-19	Initiated	B. Riley FBR	Buy	$9
Feb-28-18	Initiated	B. Riley FBR, Inc.	Buy	$10
Jul-11-17	Initiated	Rodman & Renshaw	Buy	$11
Mar-22-17	Initiated	JMP Securities	Mkt Outperform
Oct-03-16	Initiated	ROTH Capital	Buy	$9

May-02-24 04:01PM	Mustang Bio Announces Closing of $4 Million Public Offering (GlobeNewswire)
May-01-24 04:01PM	Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer (GlobeNewswire)
Apr-29-24 08:00PM	Mustang Bio Announces Pricing of $4 Million Public Offering (GlobeNewswire)
08:00AM	Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds (GlobeNewswire)
Apr-25-24 08:30AM	Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024 (GlobeNewswire)
07:30AM	Loading…
Apr-24-24 07:30AM	Avenue Therapeutics Announces Reverse Stock Split (GlobeNewswire)
Apr-11-24 12:24PM	3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024 (InvestorPlace)
Mar-28-24 10:53PM	FBIO Stock Earnings: Fortress Biotech Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -7.83%
04:05PM	Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
09:00AM	Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases (GlobeNewswire)
Mar-25-24 08:30AM	Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024 (GlobeNewswire)
Mar-22-24 08:30AM	Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-21-24 04:01PM	Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-18-24 04:05PM	Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:30AM	Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea (GlobeNewswire)
08:00AM	Loading…
08:00AM	Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors (GlobeNewswire)
Mar-15-24 08:30AM	Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 (GlobeNewswire) +15.18%
08:15AM	Avenue Therapeutics Receives Positive Listing Determination from Nasdaq (GlobeNewswire)
Mar-13-24 08:30AM	Journey Medical Corporation to Participate in the 36th Annual ROTH Conference (GlobeNewswire) -5.45%
Mar-12-24 08:30AM	Fortress Biotech to Participate in 36th Annual ROTH Conference (GlobeNewswire)
Mar-11-24 04:05PM	Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:30AM	Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting (GlobeNewswire)
08:00AM	Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting (GlobeNewswire)
Mar-07-24 07:30AM	Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13R 2-targeted CAR T-Cells in High-Grade Glioma (GlobeNewswire) -6.55%
Mar-04-24 08:30AM	Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease (GlobeNewswire) -5.76%
Feb-22-24 08:30AM	Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy (GlobeNewswire)
Feb-02-24 02:40PM	Lindsay Rosenwalds Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries (News Direct) -6.09%
Jan-29-24 08:00AM	Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market (GlobeNewswire)
Jan-11-24 08:30AM	Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference (GlobeNewswire)
08:15AM	Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference (GlobeNewswire)
08:00AM	Loading…
08:00AM	Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference (GlobeNewswire)
Jan-09-24 05:02PM	Insider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires 50,000 ... (GuruFocus.com) -6.19%
Jan-05-24 09:15AM	Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds (GlobeNewswire)
08:30AM	Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea (GlobeNewswire)
Jan-04-24 08:30AM	Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol (GlobeNewswire)
Jan-03-24 04:01PM	Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -7.81%
Jan-02-24 04:05PM	Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million (GlobeNewswire) -10.63%
08:30AM	Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) (GlobeNewswire)
Dec-29-23 08:20AM	Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -22.62%
Dec-11-23 08:30AM	Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-06-23 08:30AM	Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics (PR Newswire)
08:30AM	Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd. (GlobeNewswire)
08:00AM	Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea (GlobeNewswire)
Dec-05-23 08:30AM	Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance (GlobeNewswire)
Dec-01-23 08:30AM	Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting (GlobeNewswire) +9.60%
Nov-16-23 11:18PM	Insider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires Shares ... (GuruFocus.com)
Nov-14-23 04:29PM	Fortress Biotech: Q3 Earnings Snapshot (Associated Press Finance)
04:10PM	Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:05PM	Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Fortress Biotech Announces Closing of $10.0 Million Public Offering (GlobeNewswire)
Nov-13-23 05:00PM	Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:05PM	Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-10-23 08:15AM	Fortress Biotech Announces Pricing of $10.0 Million Public Offering (GlobeNewswire) -37.02%
Nov-09-23 05:05PM	Fortress Biotech Announces Launch of Proposed Public Offering (GlobeNewswire)
Nov-07-23 04:01PM	Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) -10.50%
Nov-02-23 03:00PM	Avenue Therapeutics Announces Closing of $5.0 Million Public Offering (GlobeNewswire) +15.48%
09:28AM	Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-23 09:15AM	Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering (GlobeNewswire) +5.29%
08:30AM	Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire)
Oct-30-23 02:15PM	Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-26-23 12:30PM	Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
09:00AM	Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13R 2 targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma (GlobeNewswire)
Oct-20-23 08:30AM	Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn (Minocycline Hydrochloride Extended-Release Tablets, 105 mg) (GlobeNewswire) -8.37%
Oct-18-23 08:30AM	Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer (GlobeNewswire) -12.69%
Oct-16-23 09:00AM	Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1 (GlobeNewswire)
Oct-09-23 12:50PM	Fortress Biotech Announces Reverse Stock Split (GlobeNewswire) -12.48%
Oct-05-23 08:30AM	Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference (GlobeNewswire)
Oct-02-23 12:53PM	Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds (GlobeNewswire) +7.85%
Sep-21-23 08:30AM	Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference (GlobeNewswire) -5.93%
Sep-07-23 08:30AM	Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
08:15AM	Mustang Bio to Participate in Upcoming September 2023 Investor Conferences (GlobeNewswire)
Sep-06-23 08:30AM	Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +9.61%
08:00AM	Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations (GlobeNewswire)
Sep-05-23 08:30AM	Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -10.79%
Aug-16-23 08:00AM	Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy (GlobeNewswire) -9.95%
Aug-14-23 04:19PM	Fortress Biotech: Q2 Earnings Snapshot (AP Finance)
04:15PM	Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:05PM	Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-10-23 04:15PM	Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-08-23 04:01PM	Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-03-23 08:30AM	Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
08:00AM	Mustang Bio to Participate in Two August 2023 Investor Conferences (GlobeNewswire)
Aug-02-23 04:01PM	Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023 (GlobeNewswire)
Aug-01-23 02:54PM	Insiders Re-Evaluate Their US$3.4m Stock Purchase As Fortress Biotech Falls To US$77m (Simply Wall St.)
08:30AM	Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study (GlobeNewswire)
Jul-31-23 08:30AM	Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences (GlobeNewswire)
08:00AM	Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market (GlobeNewswire)
Jul-27-23 08:30AM	Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) (GlobeNewswire)
07:00AM	Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma (GlobeNewswire)
Jul-25-23 08:30AM	Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol (GlobeNewswire) -16.57%
Jul-19-23 08:30AM	Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023 (GlobeNewswire)
Jul-11-23 08:30AM	Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults (GlobeNewswire)
Jul-06-23 08:00AM	Mustang Bio Announces Participation in Upcoming Scientific Meetings (GlobeNewswire) -5.04%
Jul-05-23 02:31PM	Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shift From Loss To Profit (Simply Wall St.)
Jul-03-23 08:00AM	Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023 (GlobeNewswire)
Jun-29-23 08:00AM	Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States (GlobeNewswire) +7.55%
Jun-28-23 08:00AM	Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing (GlobeNewswire) -5.69%
Jun-15-23 04:01PM	Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy (GlobeNewswire) +10.55%
08:00AM	Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program (GlobeNewswire)

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Jan 05 '24	Buy	2.38	50,000	118,770	2,863,905	Jan 09 08:15 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Nov 14 '23	Buy	1.70	1,567,515	2,664,776	2,597,440	Nov 16 05:50 PM
WEISS MICHAEL S	See Remarks	Nov 14 '23	Buy	1.70	147,058	249,999	1,130,520	Nov 16 05:46 PM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Sep 26 '23	Buy	0.28	100,000	28,330	15,449,091	Sep 27 08:20 AM
Fortress Biotech, Inc.	10% Owner	Sep 08 '23	Buy	0.72	418,410	301,255	1,032,390	Sep 12 09:02 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Aug 18 '23	Buy	9.34	10,000	93,400	112,500	Aug 21 08:30 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Aug 17 '23	Buy	11.75	10,000	117,500	102,500	Aug 21 08:30 AM

Open in Screener

TGTX

TG Therapeutics Inc

May 02 • 04:00PM ET

16.42

Dollar change +0.54
Percentage change 3.40	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

TGTX TG Therapeutics Inc daily Stock Chart

Held by: VTI VB IWM VXF VBK IWO SCHA VTWO VHT PBE

Index	RUT	P/E	74.47	EPS (ttm)	0.22	Insider Own	9.56%	Shs Outstand	151.42M	Perf Week	18.04%
Market Cap	2.54B	Forward P/E	27.71	EPS next Y	0.59	Insider Trans	-0.62%	Shs Float	139.77M	Perf Month	13.48%
Income	41.20M	PEG	-	EPS next Q	-0.04	Inst Own	58.57%	Short Float	25.55%	Perf Quarter	-2.73%
Sales	289.33M	P/S	8.77	EPS this Y	-138.27%	Inst Trans	-5.76%	Short Ratio	9.38	Perf Half Y	112.42%
Book/sh	1.06	P/B	15.49	EPS next Y	1820.18%	ROA	14.44%	Short Interest	35.71M	Perf Year	-47.30%
Cash/sh	1.36	P/C	12.10	EPS next 5Y	-	ROE	43.93%	52W Range	6.46 - 35.67	Perf YTD	-3.86%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	15.27%	52W High	-53.97%	Beta	2.28
Dividend TTM	-	Quick Ratio	5.18	Sales past 5Y	2506.46%	Gross Margin	93.53%	52W Low	154.18%	ATR (14)	0.95
Dividend Ex-Date	-	Current Ratio	5.92	EPS Y/Y TTM	123.31%	Oper. Margin	16.71%	RSI (14)	67.22	Volatility	8.87% 5.38%
Employees	264	Debt/Eq	0.69	Sales Y/Y TTM	3275.73%	Profit Margin	14.24%	Recom	1.56	Target Price	31.50
Option/Short	Yes / Yes	LT Debt/Eq	0.68	EPS Q/Q	73.82%	Payout	0.00%	Rel Volume	2.29	Prev Close	15.88
Sales Surprise	16.25%	EPS Surprise	-16.67%	Sales Q/Q	713.46%	Earnings	May 01 BMO	Avg Volume	3.81M	Price	16.42
SMA20	15.26%	SMA50	8.84%	SMA200	22.80%	Trades		Volume	8,549,317	Change	3.40%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-02-23	Upgrade	Goldman	Sell → Neutral	$16 → $12
Jun-26-23	Resumed	Jefferies	Buy	$55 → $40
May-20-22	Initiated	BofA Securities	Underperform	$5
Feb-23-22	Reiterated	B. Riley Securities	Buy	$49 → $35
Nov-15-21	Downgrade	Goldman	Neutral → Sell	$33 → $26
Apr-20-21	Initiated	Goldman	Neutral	$50
Apr-19-21	Reiterated	H.C. Wainwright	Buy	$79 → $89
Sep-01-20	Initiated	JP Morgan	Overweight	$38
Aug-11-20	Reiterated	H.C. Wainwright	Buy	$32 → $38
Jun-05-20	Initiated	Evercore ISI	Outperform	$60
Jan-17-20	Reiterated	H.C. Wainwright	Buy	$20 → $24
Nov-27-19	Resumed	B. Riley FBR	Buy	$12
Feb-06-19	Resumed	Jefferies	Buy	$8
Sep-25-18	Downgrade	Raymond James	Strong Buy → Outperform
Mar-09-18	Reiterated	B. Riley FBR, Inc.	Buy	$21.50 → $27
Dec-01-17	Resumed	B. Riley FBR, Inc.	Buy	$21.50
Nov-14-17	Resumed	H.C. Wainwright	Buy	$33
Apr-25-17	Initiated	Jefferies	Buy
Mar-06-17	Reiterated	FBR & Co.	Outperform	$24 → $26
Oct-06-16	Resumed	Brean Capital	Buy	$28

Show Previous Ratings

Today 05:56AM	Why TG Therapeutics Stock Was Rocketing Higher This Week (Motley Fool)
May-02-24 03:05AM	TG Therapeutics Inc (TGTX) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue Growth ... (GuruFocus.com)
12:27AM	Q1 2024 TG Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-01-24 11:53AM	TGTX Stock Earnings: TG Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace) +16.25%
08:34AM	TG Therapeutics Inc (TGTX) Surpasses Revenue Estimates in Q1 2024, Despite Widening Net Loss (GuruFocus.com)
08:30AM	Loading…
08:30AM	TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:32AM	TG Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-30-24 04:55PM	TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update (GlobeNewswire)
09:35AM	After Plunging -9.82% in 4 Weeks, Here's Why the Trend Might Reverse for TG Therapeutics (TGTX) (Zacks)
Apr-27-24 09:37AM	10 Best Languages to Learn for the Future (Insider Monkey)
Apr-18-24 07:30AM	TG Therapeutics Announces Additional Data Presentations for BRIUMVI (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting (GlobeNewswire)
07:00AM	TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis (GlobeNewswire)
Apr-15-24 07:30AM	TG Therapeutics Announces Presentation of Data for BRIUMVI (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting (GlobeNewswire)
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
07:30AM	Loading…
Mar-08-24 07:30AM	TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting (GlobeNewswire) -6.78%
Mar-01-24 07:30AM	TG Therapeutics Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum (GlobeNewswire)
Feb-29-24 09:22AM	TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 10:24PM	Q4 2023 TG Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +26.74%
04:05PM	TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares? (Investor's Business Daily)
08:10AM	TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:52AM	TG Therapeutics Inc (TGTX) Announces Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
07:21AM	TG Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results (GlobeNewswire)
Feb-27-24 07:30AM	TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI (ublituximab-xiiy) (GlobeNewswire)
Feb-26-24 07:00AM	TG Therapeutics Announces European Launch of BRIUMVI (ublituximab-xiiy) (GlobeNewswire)
Feb-23-24 07:30AM	TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update (GlobeNewswire)
Feb-20-24 10:00AM	Will TG Therapeutics (TGTX) Report Negative Q4 Earnings? What You Should Know (Zacks)
07:30AM	TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum (GlobeNewswire)
Feb-13-24 07:20AM	Precision receives payments from TG Therapeutics for azer-cel (Pharmaceutical Business Review) -8.23%
06:30AM	Loading…
Jan-22-24 06:30AM	7 Exciting Stocks Poised for Explosive Growth in Key Sectors (InvestorPlace) +7.63%
Jan-10-24 04:09PM	TG Therapeutics Reverses Its 225% Winning Streak On Lackluster Guidance (Investor's Business Daily) -15.42%
09:33AM	TG Therapeutics Adds To Its 225% Sprint After MS Drug Crushes Sales Estimates (Investor's Business Daily)
07:00AM	TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones (GlobeNewswire)
Jan-09-24 09:03AM	Director Laurence Charney Sells 17,500 Shares of TG Therapeutics Inc (GuruFocus.com)
07:00AM	TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision's Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases (GlobeNewswire)
Jan-06-24 05:02AM	Insider Sell: CFO Sean Power Sells 47,867 Shares of TG Therapeutics Inc (TGTX) (GuruFocus.com)
Jan-05-24 07:30AM	TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +9.05%
Dec-15-23 10:22AM	11 Most Promising Biotech Stocks to Buy According to Analysts (Insider Monkey)
Dec-07-23 03:31PM	TG Therapeutics Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating (Investor's Business Daily)
Nov-27-23 07:30AM	TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-06-23 09:55AM	Does TG Therapeutics (TGTX) Have the Potential to Rally 127.76% as Wall Street Analysts Expect? (Zacks) -7.32%
09:27AM	TG Therapeutics, Inc. (NASDAQ:TGTX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 07:30AM	TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference (GlobeNewswire) +6.24%
Nov-01-23 12:18PM	Why TG Therapeutics Stock Is Crushing It Today (Motley Fool) +30.92%
10:21AM	Morning Brew: AMD's Q4 Guidance Weighs on Stock, Apple's Negative Sentiment Overcooked, and Fed (GuruFocus.com)
09:17AM	TG Therapeutics Inc (TGTX) Reports Third Quarter 2023 Financial Results (GuruFocus.com)
07:43AM	TG Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-30-23 07:30AM	TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update (GlobeNewswire) +6.18%
Oct-14-23 01:15PM	13 Stocks to Buy with Exponential Growth (Insider Monkey)
Oct-12-23 11:00AM	TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting (GlobeNewswire)
Oct-11-23 10:30AM	TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting (GlobeNewswire)
Oct-06-23 08:30AM	Do Options Traders Know Something About TG Therapeutics (TGTX) Stock We Don't? (Zacks)
Oct-02-23 07:30AM	TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting (GlobeNewswire)
Sep-28-23 10:17AM	15 Best U.S. Stocks to Buy Now Under $10 (Insider Monkey)
Sep-22-23 07:30AM	TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-07-23 07:30AM	TG Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Sep-06-23 01:06PM	Unraveling the Future of TG Therapeutics Inc (TGTX): A Deep Dive into Key Metrics (GuruFocus.com)
Aug-29-23 12:43AM	3 Very Oversold Biotech Stocks to Buy Right Now (InvestorPlace)
Aug-19-23 11:22AM	Buffett goes big on homebuilders: Insider trades & hedge funds weekly (Investing.com)
Aug-12-23 11:05AM	10 Oversold Healthcare Stocks to Buy (Insider Monkey)
Aug-04-23 06:20AM	TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates (Simply Wall St.)
Aug-03-23 06:10AM	New Forecasts: Here's What Analysts Think The Future Holds For TG Therapeutics, Inc. (NASDAQ:TGTX) (Simply Wall St.) +6.16%
Aug-01-23 04:04PM	Sales Of TG Therapeutics' New Product Doubled Here's Why Shares Halved (Investor's Business Daily) -49.30%
02:28PM	Morrisville pharma inks deal worth close to $650 million (American City Business Journals)
11:50AM	Why TG Therapeutics Stock Is Crashing Today (Motley Fool)
08:35AM	TG Therapeutics (TGTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:28AM	TG Therapeutics: Q2 Earnings Snapshot (AP Finance)
07:15AM	TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
07:00AM	TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy) (GlobeNewswire)
Jul-31-23 08:30AM	TG Therapeutics to Host Conference Call on Second Quarter 2023 Financial Results and Business Update (GlobeNewswire) +5.03%
Jul-25-23 11:46AM	InMode (INMD) to Post Q2 Earnings: What's in the Cards? (Zacks)
10:57AM	What's in Store for Canopy Growth (CGC) in Q1 Earnings? (Zacks)
Jul-24-23 09:35AM	Down -12.63% in 4 Weeks, Here's Why You Should You Buy the Dip in TG Therapeutics (TGTX) (Zacks)
Jul-21-23 12:30PM	Hologic (HOLX) to Report Q3 Earnings: What's in the Cards? (Zacks)
Jul-13-23 04:05PM	How Roche Just Cut Top 1% Biotech Stock TG Therapeutics Down A Peg (Investor's Business Daily) -14.57%
Jul-10-23 02:01AM	Quanterix Corporation (QTRX) Surges 13.6%: Is This an Indication of Further Gains? (Zacks) +6.17%
Jul-03-23 09:00AM	Top Growth Stocks for July 2023 (Investopedia) -8.41%
Jul-01-23 09:00AM	Top Stocks for July 2023 (Investopedia)
Jun-27-23 09:22AM	Despite shrinking by US$188m in the past week, TG Therapeutics (NASDAQ:TGTX) shareholders are still up 427% over 1 year (Simply Wall St.)
06:46AM	Daily Vickers Top Buyers & Sellers for 06/27/2023 (Argus Research)
Jun-08-23 08:30AM	A Pullback in TG Therapeutics Looks Like a Buying Opportunity (TheStreet.com) +7.33%
Jun-06-23 01:13PM	Top Small-Cap Stocks for June 2023 (Investopedia)
Jun-05-23 07:30AM	TG Therapeutics to Participate in the 2023 Jefferies Healthcare Conference (GlobeNewswire)
Jun-02-23 09:15AM	TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting (GlobeNewswire)
Jun-01-23 09:15AM	TG Therapeutics Announces European Commission Approval for BRIUMVI® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults (GlobeNewswire)
May-31-23 07:30AM	TG Therapeutics Announces Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting (GlobeNewswire)
May-18-23 11:05AM	When Will TG Therapeutics, Inc. (NASDAQ:TGTX) Turn A Profit? (Simply Wall St.)
May-04-23 10:16AM	TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2023 Earnings Call Transcript (Insider Monkey)
07:30AM	TG Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference (GlobeNewswire)
May-01-23 10:32PM	Q1 2023 TG Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +23.40%
04:28PM	Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today (Motley Fool)
04:03PM	Top 1% Biotech TG Therapeutics Obliterates Bullish Sales Calls And Rockets (Investor's Business Daily)
08:45AM	TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-28-23 04:30PM	TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update (GlobeNewswire) +6.43%
Apr-27-23 07:30AM	TG Therapeutics Announces Issuance of Permanent J-Code for BRIUMVI® (ublituximab-xiiy) from Centers for Medicare and Medicaid Services (GlobeNewswire) +5.57%
Apr-25-23 08:45AM	3 Top Biotech Stocks Defying the Bear Market (Motley Fool)
08:00AM	TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 75th Annual Meeting (GlobeNewswire)

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lonial Sagar	Director	Mar 13 '24	Sale	15.94	5,000	79,675	108,878	Mar 15 04:37 PM
Charney Laurence N	Director	Mar 12 '24	Sale	15.97	22,000	351,340	215,229	Mar 13 04:52 PM
Charney Laurence N	Director	Jan 05 '24	Sale	19.03	17,500	333,025	237,229	Jan 08 06:33 PM
Power Sean A	CFO	Jan 03 '24	Sale	16.91	47,867	809,431	606,969	Jan 05 05:00 PM
WEISS MICHAEL S	CEO and President	Aug 11 '23	Buy	10.13	100,000	1,013,000	12,073,021	Aug 14 09:54 AM
Lonial Sagar	Director	Jun 23 '23	Sale	23.37	34,854	814,538	93,878	Jun 26 05:00 PM
Power Sean A	Chief Financial Officer	Jun 02 '23	Sale	26.70	73,647	1,966,375	654,836	Jun 05 06:26 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

FBIO

Fortress Biotech Inc

TGTX

TG Therapeutics Inc

Upgrade your FINVIZ experience